CTRI/2023/09/057359尚未招募2 期
Estrogen Receptor-Beta & TP53 Status as prognostic markers in Triple Negative Breast Cancer and their clinical outcomes with Tamoxifen(Selective Estrogen Receptor Modulator) - NI
AVNEET KAILASH AGRAWA0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)All triple negative breast cancer patients will be included
- •2)All stages of breast cancer patients will be included
排除标准
- •1)Luminal Breast Cancer patients
- •2)Pregnant females
- •3)Breastfeeding females
- •4)Patients receiving olaparib
研究者
相似试验
已完成
不适用
Estrogen Receptor Beta (ER-ß) as a coadjuvant target of neoadjuvant endocrine therapyMalignant neoplasm of breastCancerBreast CancerISRCTN89801719Federal University of Sao Paulo (Brazil)90
尚未招募
Unknown
Evaluating utility of Oestrogen and Progesterone Receptor biomarkers for prediction of colorectal CancerCTRI/2024/05/068054Datta Meghe Institute of Higher Education & Research (DMIHER)
招募中
2 期
4FMFES-PET Imaging of ER+ Advanced Breast CancersER+ Breast CancerNCT04824014Centre de recherche du Centre hospitalier universitaire de Sherbrooke150
招募中
1 期
EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patientsWomen with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitorMedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2023-506282-66-00Institut Curie300
已完成
2 期
Effects of estrogen on prognosis of patient with diffuse axonal injury due to severe traumatic brain injuryIRCT2014091919227N1Vice chanscellor for research, Tabriz University of Medical Sciences